COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020

NCT04723290 | Completed DMC

• 1 other identifier: SERO-SARS-CoV-2 GHdC
• Study Type: interventional
• Target: 2,817
• Locations: 1 country
• Sites: 1

Brief Summary

The management of the Grand Hôpital de Charleroi hospital authorized the performance of a serology for each member of the establishment's staff in order to better characterize the proportion of its employees who have already been in contact with the SARS CoV-2 virus for organizational and evaluation purposes symptoms.

Conditions

Covid19

Outcome Measures

Primary Outcomes (1)

• Serological tests to know the level of antibodies against SARS CoV-2

  The hospital has organized several schedules and appointments for each staff member depending on the ability to analyze laboratory samples and blood draws.

  up to 6 weeks

Study Arms (1)

Serological tests

EXPERIMENTAL

All staff at GHdC who want to know their level of antibodies against SARS CoV-2

Diagnostic Test: Serological tests for SARS Cov-2

Interventions

Serological tests for SARS Cov-2 DIAGNOSTIC_TEST

Each participant will have a blood test on a dry tube of maximum 8 ml of whole blood

Serological tests

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Be a member of the staff of the Grand Hôpital de Charleroi who wishes to participate in order to know their immunity related to SARS CoV-2 after the first wave of pandemic.

You may not qualify if:

• Not be part of the staff of the Grand Hôpital de Charleroi.

Sponsors & Collaborators

• Grand Hôpital de Charleroi: lead

Study Sites (1)

Grand Hôpital de Charleroi

Charleroi, Hainaut, 6060, Belgium

Location

Related Publications (1)

• de Visscher N, Holemans X, Gillain A, Kornreich A, Lagasse R, Piette P, Ventura M, Thys F. SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves. Viruses. 2022 Jul 14;14(7):1535. doi: 10.3390/v14071535.

  PMID: 35891515 DERIVED

MeSH Terms

Conditions

COVID-19

Interventions

Serologic Tests

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Immunologic Tests; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques; Immunologic Techniques

Study Officials

• Nathalie de Visscher, MD

  Grand Hôpital de Charleroi

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 21, 2021
• First Posted: January 25, 2021
• Study Start: June 20, 2020
• Primary Completion: October 31, 2020
• Study Completion: December 31, 2020
• Last Updated: March 25, 2021

Record last verified: 2021-03

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)